+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free

Malignant Mesothelioma Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2025

Pre Book Price: $ 5216

Original Price: $ 5795

Malignant mesothelioma is deadly and rare type of cancer that affects the mesothelium, a membrane that forms a thin lining of the body's internal organs (pleurae, peritoneum, and pericardium). The mesothelium makes a special lubricating fluid that helps to protect the organs and allows organs to move against each other. Some major symptoms include shortness of breath, chest pain, and cough. It takes around 35 to 50 years for the symptoms to manifest. Malignant Mesothelioma, can occur at any age; however, it is common in adults aged 65 and above. It is more common in men as compared to women, the male to female ratio is 3:1. Malignant mesothelioma accounts for 1% of all cancers worldwide. People exposed to asbestos (industrial pollutant), are at a higher risk of developing malignant mesothelioma. The risk of mesothelioma is increased in polluted areas by 2 to 10 fold as compared to non-polluted areas. Additionally, people who are exposed to a high dose of radiation, zeolites (minerals chemically related to asbestos), and suffering from simian virus 40 infection are at a risk of developing malignant mesothelioma. 

In terms of type, the malignant mesothelioma market can be segmented into malignant pleural mesothelioma (occurs in the lining of the lungs), malignant peritoneal mesothelioma (occurs in the lining of the abdomen), and malignant pericardial mesothelioma (occurs in the lining of the heart). The malignant pleural mesothelioma segment is anticipated to grow because it accounts 70% of all mesothelioma cases followed by malignant peritoneal mesothelioma which accounts 15-20% of all mesothelioma cases. In terms of treatment, the malignant mesothelioma market can be segmented into surgery, chemotherapy, and radiotherapy. Surgery includes pneumonectomy, debulking, and omentectomy and is preferred treatment for malignant mesothelioma. Patients who successfully underwent surgical resection have a high surveillance rate (significantly 5 years). Radiation helps to shrink the tumor size and is often used as an adjuvant therapy. Chemotherapy plays an important role in palliative care. A number of companies such as AstraZeneca are involved in research and development of therapeutics for malignant mesothelioma. Major pipeline molecules include durvalumab, tazemetostat, tremelimumab, nintedanib, ADI-PEG 20, and HSV 1716. Therapeutic pipeline is anticipated to witness considerable growth in the malignant mesothelioma market in the near future due to increase in incidence rate, rising air pollution, rising geriatric population, and increase healthcare expenditure. Additionally, the development of novel therapy and introduction to advance treatment options are likely to provide lucrative growth opportunities to the malignant mesothelioma market during the forecast period. However, long latent period between onset and symptom, lack of effective treatment, and low surveillance rate are key factors that restrain the malignant mesothelioma market. 

In terms of geography, the malignant mesothelioma market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America leads the malignant mesothelioma market, followed by Europe, due to the higher incidence and prevalence rate, rise in the geriatric population, and increase in demand for advance treatment. Asia Pacific is an emerging market for malignant mesothelioma due to the developing healthcare infrastructure, increase in patient awareness, and rising government expenditure in the healthcare industry. However, poor patient awareness, lack of proper treatment, and high cost of therapy are factors restraining the malignant mesothelioma market in Middle East & Africa. 

Major players operating in the malignant mesothelioma market include Eli Lilly and Company, AstraZeneca plc, Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Epizyme, Inc, Bayer AG, Aduro Biotech, Ono Pharmaceutical Co., Ltd., Polaris Pharmaceuticals, Inc., Calithera Biosciences, Inc., and CBT Pharmaceuticals, Inc.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on:

  • Market segments and sub-segments
  • Market trends and dynamics
  • Supply and demand
  • Market size
  • Current trends/opportunities/challenges
  • Competitive landscape
  • Technological breakthroughs
  • Value chain and stakeholder analysis

The regional analysis covers:

  • North America (U.S. and Canada)
  • Latin America (Mexico, Brazil, Peru, Chile, and others)
  • Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
  • Eastern Europe (Poland and Russia)
  • Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
  • Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

  • A complete backdrop analysis, which includes an assessment of the parent market
  • Important changes in market dynamics
  • Market segmentation up to the second or third level
  • Historical, current, and projected size of the market from the standpoint of both value and volume
  • Reporting and evaluation of recent industry developments
  • Market shares and strategies of key players
  • Emerging niche segments and regional markets
  • An objective assessment of the trajectory of the market
  • Recommendations to companies for strengthening their foothold in the market    

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.


Note : All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Transparency Market Research.


To receive discount, please click on the button below.

Please click on the button below to customize this report.

 
 
Back To Top